10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 62,592 | $3,016,934 | -40% | 0.02% |
| 2. | Antipodes Partners Jacob Mitchell | 45,361 | $2,186,400 | -2% | 0.04% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,753,764 | $84,531,425 | 0.05% | |
| 2. | 750,000 | $36,150,000 | 1.21% | |
| 3. | 391,809 | $18,885,194 | 0.03% | |
| 4. | 331,867 | $15,995,989 | 0.01% | |
| 5. | 245,043 | $11,811,058 | 0.05% |